References
- Trinchieri G. Interleukin-12: A cytokine at the interface of inflammation and immunity. Advances in Immunology 1998; 70: 83–243
- Lenschow D J, Walunas T L, Bluestone J A. CD28/B7 system of T cell costimulation Annual Review Immunology 1996; 14: 233–58
- Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini P L, Colombo M P, Forni G. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. Journal of Experimental Medicine 1998; 188: 589–96
- Nagouchi Y, Jungbluth A, Richards E C, Old L J. Effect of interleukin 12 on tumor induction by 3-methlycholanthrene. Proc. Natl. Acad. Sci. USA 1996; 93: 11798–11801
- Atkins M B, Robertson M J, Gordon M, Lotze M T, DeCoste M, DuBois JS, Ritz J, Sandier A B, Edington H D, Garzone P D, Mier J W, Canning CM, Battiato L, Tahara H, Sherman M L. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies Clin. Cancer Research 1997; 3: 409–417
- Leonard J P, Sherman M L, Fisher G L, Buchanan L J, Larsen G, Atkins M B, Sosman J A, Dutcher J P, Vogelzang N J, Ryan J L. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-y production. Blood 1997; 90: 2541–2548
- Rook A H, Wood G S, Yoo E K, Elentisas R, Kao D M. F, Sherman M L, Witmer W K, Rockwell K A, Shane R B, Lessin S R, Vonderheid E C. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999; 94: 902–908
- Pluda JM, Wyvill K, Little R, Lietzau J, Shearer G, Tosato G, Feigal E, Bhougnet C, Fowke K, Yarchoan R. Administration of interleukin 12 (IL-12) to patients with aids-associated kaposi's sarcoma at the national cancer institute. National AIDS malignancy conference abstract. 1999
- Orange J S, Wolf S F, Biron C A. Effects of IL12 on the response and susceptibility to experimental viral infections. Journal of Immunology 1994; 152: 1253–1264
- Kurzawa H, Wysocka M, Aruga E, Chang A E, Trinchieri G, Lee W M. F. Recombinant Interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression. Cancer Research 1998; 58: 491–499
- Swiniarski H, Sturmhoefel K, Lee K, Gray G S, Thomas J L, Wolf S F, Dorner A J, O'Toole M. Immune response enhancement by in vivo administration of b7.2Ig, a soluble costimulatory protein. Journal of Clinical Investigation 1999; 92: 235–245
- Sturmhoefel K, Lee K, Gray G S, Thomas J, Zollner R, O'Toole M, Swiniarski H, Dorner A, Wolf S F. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant. Cancer Research 1999; 59: 4964–4972